GHK-Cu Copper Peptide: Skin Repair and Collagen Research
PeptaBase Research Review | 2026-03-10
What GHK-Cu Is
GHK-Cu is a tripeptide (Gly-His-Lys) complexed with copper. Published literature from Loren Pickart and collaborators identified this complex in human plasma and investigated its biological signaling properties in skin-related models.
Published human studies and biochemical literature report that endogenous GHK concentrations vary with age. This observation has been investigated as a potential factor in age-associated changes in tissue-remodeling biology.
Mechanisms Studied
Collagen Production
GHK-Cu has been studied in fibroblast and tissue-remodeling models for effects on collagen-related pathways. Published research shows modulation of extracellular-matrix signaling, including collagen synthesis and matrix-remodeling enzymes.
Antioxidant Activity
GHK-Cu has been investigated for antioxidant-associated effects in skin biology models. Published research shows associations with oxidative-stress pathway modulation in preclinical systems.
Blood Vessel Growth
In wound-healing models, GHK-Cu has been studied for angiogenesis-related signaling. Published research shows effects on pathways associated with new vessel formation in experimental settings.
Wound Closure
Preclinical wound-healing studies have investigated GHK-Cu for tissue-repair outcomes, including closure dynamics and scar-related parameters. Findings vary by model design and formulation conditions.
Skin Penetration
Clinical literature and formulation research have investigated whether GHK-Cu can penetrate skin barriers and reach dermal targets. Published studies with labeled compounds report measurable penetration under specific experimental conditions, with outcomes influenced by pH, vehicle, and concentration.
Published cosmetic-science literature therefore emphasizes formulation variables when evaluating GHK-Cu skin-delivery performance.
Topical vs. Injection
Published research on skin endpoints has primarily investigated topical formulations. Controlled trials and preclinical protocols also include non-topical administration in some contexts, but skin-focused literature is predominantly formulation-based.
Clinical literature evaluating route-dependent outcomes remains limited and heterogeneous, and copper-exposure considerations are discussed in safety-focused publications.
Evidence Level
Published research includes in vitro studies, preclinical models, and a limited body of published human studies. Controlled trials in humans are fewer in number and generally small, so interpretation depends on study design, endpoints, and formulation specifics.
Overall, GHK-Cu has been investigated across multiple research domains, while the clinical literature remains narrower than for fully approved therapeutic drugs.
--- For research use only. Not medical advice.